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The Fragile X-related disorders are a group of genetic conditions that include the neu-
rodegenerative disorder, Fragile X-associated tremor/ataxia syndrome (FXTAS), the fertility
disorder, Fragile X-associated primary ovarian insufﬁciency (FXPOI) and the intellectual
disability, Fragile X syndrome (FXS). The pathology in all these diseases is related to the
number of CGG/CCG-repeats in the 5′ UTR of the Fragile X mental retardation 1 (FMR1)
gene. The repeats are prone to continuous expansion and the increase in repeat number
has paradoxical effects on gene expression increasing transcription onmid-sized alleles and
decreasing it on longer ones. In some cases the repeats can simultaneously both increase
FMR1 mRNA production and decrease the levels of the FMR1 gene product, Fragile X
mental retardation 1 protein (FMRP). Since FXTAS and FXPOI result from the deleterious
consequences of the expression of elevated levels of FMR1 mRNA and FXS is caused
by an FMRP deﬁciency, the clinical picture is turning out to be more complex than once
appreciated. Added complications result from the fact that increasing repeat numbersmake
the alleles somatically unstable.Thus many individuals have a complex mixture of different
sized alleles in different cells. Furthermore, it has become apparent that the eponymous
fragile site, once thought to be no more than a useful diagnostic criterion, may have clinical
consequences for females who inherit chromosomes that express this site. This review
will cover what is currently known about the mechanisms responsible for repeat instability,
for the repeat-mediated epigenetic changes that affect expression of the FMR1 gene, and
for chromosome fragility. It will also touch on what current and future options are for
ameliorating some of these effects.
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INTRODUCTION
The Fragile X-related disorders (FXDs) are members of a large
and growing group of human genetic conditions known as the
repeat expansion diseases (Fry and Usdin, 2006). These diseases
all have an unusual mutational mechanism: the causative lesion is
an increase in the number of repeats (“expansion”) at a speciﬁc
tandem repeat tract. In the case of the FXDs, the repeat unit is
CGG/CCG and the repeat tract is located on the long arm of the X
chromosome in the 5′ untranslated region of the Fragile X mental
retardation 1 (FMR1) gene (Fu et al., 1991; Verkerk et al., 1991).
This gene encodes Fragile X mental retardation 1 protein (FMRP),
a protein important for learning and memory. Increasing repeat
number is associated with increased instability of the repeat tract
(Ashley-Koch et al., 1998; Nolin et al., 2011). The repeat number
also has bearing on the severity of the FXD symptoms although,
as will be described in more detail later, the relationship between
repeat number and pathology is not always linear.
Alleles with <45 repeats are considered to be clinically unaf-
fected and to have a very low risk of expansion, while alleles
with >54 repeats confer risk of one or more of the FXDs as well
as some risk of further expansion. Two pathological allele size
classes are usually distinguished: alleles with 55–200 repeats are
considered to be premutation (PM) alleles, while alleles with>200
repeats are referred to as full mutation (FM) alleles. PM alleles
confer risk of an adult-onset neurodegenerative disorder known
as Fragile X-associated tremor/ataxia syndrome (FXTAS) and/or
a form of ovarian dysfunction known as Fragile X-associated pri-
mary ovarian insufﬁciency (FXPOI). In contrast, FM alleles are
associated with Fragile X syndrome (FXS), the leading heritable
cause of intellectual disability (Fu et al., 1991; Verkerk et al., 1991).
This review will brieﬂy summarize some of the clinical features
of the FXDs (the reader is referred to much more comprehensive
discussions of this topic elsewhere in this issue) and then dis-
cuss current thinking about the underlying expansion mutation
responsible for these diseases alongwith two speciﬁc consequences
of this expansion, the chromosome fragility that gives these disor-
ders their name and the repeat-mediated epigenetic changes that
contribute to disease pathology.
FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME
FragileX-associated tremor/ataxia syndrome is an adult onset neu-
rodegenerative disorder whose symptoms include cerebellar ataxia
and intention tremor [reviewed in (Hagerman, 2013)]. Cogni-
tive decline or impairment, peripheral neuropathy, Parkinsonism,
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and urinary and bowel incontinence may also be seen. Magnetic
resonance imaging (MRI) ﬁndings include global brain atrophy,
enlarged ventricles, white matter disease, and increased signals in
themiddle cerebellar peduncle. In addition, characteristic intranu-
clear inclusions are seen in the brains and other organs of affected
individuals. These inclusions are tau- and synuclein negative but
contain FMR1 mRNA (Tassone et al., 2004) and a wide variety
of other proteins (Iwahashi et al., 2006; Sellier et al., 2013). In
general the severity of the FXTAS symptoms are directly related
to the length of the CGG/CCG -repeat tract (Leehey et al., 2008)
and there is a similar relationship between repeat number and the
extent of FMR1 transcription in the PM range (Kenneson et al.,
2001). However, the clinical symptoms and rate of progression
of FXTAS vary and a life expectancy of anywhere between 5 and
25 years after the onset of symptoms is seen (Seritan et al., 2008).
Males tend to bemore severely affected than females, due at least in
part to the protective effect of the secondXchromosome in females
(Berry-Kravis et al., 2005; Jacquemont, 2005; Coffey et al., 2008;
Rodriguez-Revenga et al., 2009; Tassone and Hagerman, 2012).
FRAGILE X PRIMARY OVARIAN INSUFFICIENCY
Fragile X-associated primary ovarian insufﬁciency is an ovarian
dysfunction disorder that presents with a spectrum of involve-
ment ranging from heavy bleeding, irregular periods or increased
rates of twinning, to infertility and menopause before the age of
40 (Sherman, 2000; Allen et al., 2007; Wittenberger et al., 2007).
FXPOI is seen in ∼20% of females carrying a PM allele (Sullivan
et al., 2011) and the PM is the leading cause of early menopause
in the general population (Murray et al., 2014). Even women who
carry the PM but do not meet the strict deﬁnition of FXPOI, tend
to reach menopause on average 5 years earlier than their sisters
without the PM (Murray et al., 2000, 2014; Sullivan et al., 2005).
Women with FXPOI show signs of early ovarian aging includ-
ing shorter than normal menstrual cycles than women who are
still cycling, increased twinning, reduced levels of anti-müllerian
hormone (AMH) indicating a reduced follicle pool, and elevated
follicle stimulating hormone (FSH; Welt et al., 2004; Rohr et al.,
2008). The risk of FXPOI shows an unusual U-shaped relation-
ship with repeat number with the highest risk being associated
with alleles that have 80–99 repeats (Ennis et al., 2006; Allen et al.,
2007; Tejada et al., 2008).
FRAGILE X SYNDROME
Fragile x syndrome is the most common heritable cause of intel-
lectual disability and the most common known monogenic cause
of autism [reviewed in (McLennan et al., 2011)]. It is associated
with a wide range of symptoms of varying severity that may
include speech and language delay, macroorchidism in males,
hyperarousal and depression. Most males and 25% of females
have cognitive impairment (IQ < 70), while nearly all patients
present with behavior problems, males typically with attention
deﬁcit hyperactivity disorder (ADHD) and aggression and females
with shyness and social withdrawal (Hagerman and Hagerman,
2008). As many as 67% of male FM carriers meet the criteria for
autism or autism spectrum disorder (ASD; Clifford et al., 2007;
Wang et al., 2010). Seizures are seen in 10–20%of affected children
(Berry-Kravis, 2002). In ∼10% of children there is also a so-called
Prader–Willi phenotype that includes severe obesity, hyperphagia
and hypogonadism or delayed puberty (Nowicki et al., 2007). At
the cellular level, FXS is associated with immature dendritic spine
morphology (Braun and Segal, 2000; Irwin et al., 2000). Amongst
the effects seen at the molecular level there is dysregulated protein
synthesis in the postsynaptic density in response to activation of
the mGluR5 receptor that results in a net increased excitability of
neuronal circuits (Bear et al., 2004; Dolen and Bear, 2008).
The FM allele is also associated with the expression of a folate-
sensitive fragile site for which the FXDs are named. This site
appears as a gap, constriction or break that is seen in metaphase
chromosomes when cells are subjected to folate-stress. In addition
to this chromosomal abnormality, a number of female FM carriers
have been shown to be mosaic for Turner syndrome (TS), a disor-
der in which one of the two X chromosomes has been lost (Shapiro
et al., 1994; Tejada et al., 1994; Wilkin et al., 2000). The symptoms
of TS include short stature, scoliosis, gonadal dysfunction, and
cognitive problems including difﬁculties with spatial-temporal
processing. Analysis of fetuses with the FM suggests that the risk
of TS is signiﬁcantly higher in female FM carriers than it is in
the general population (Dobkin et al., 2009). Furthermore, unlike
TS in the general population where the paternal X chromosome
is more likely to be lost (Pelotti et al., 2003), in FX-related TS, it
is the maternally transmitted chromosome carrying the FM allele
(Dobkin et al., 2009).
FXS IS A LOSS-OF-FUNCTION DISORDER WHILE FXTAS AND FXPOI ARE
GAIN-OF-FUNCTION DISORDERS
Individuals carrying intragenic loss of function mutations in the
FMR1 gene show symptoms very similar to those carrying repeat
expansions in the FM range (De Boulle et al., 1993; Gu et al., 1994;
Lugenbeel et al., 1995; Myrick et al., 2014) and the disruption of
the FMR1 gene in mice leads to the recapitulation of some aspects
of FXS pathology including the increased density of immature
dendritic spines (Comery et al., 1997). These data support the
idea that FXS results from a failure to produce functional FMRP
(Pieretti et al., 1991; Sutcliffe et al., 1992).
Since individuals with FXTAS and FXPOI make more FMRP
than FM carriers who do not show signs of neurodegeneration or
ovarian dysfunction, the symptoms of these disorders are thought
to result from a gain of function of the transcript containing a large
CGG-repeat tract. This gain of function may be related to the abil-
ity of transcripts containing the repeats to sequester CGG-repeat
binding proteins, such as Sam68 (Sellier et al., 2010), DROSHA
and DCR8 (Sellier et al., 2013) and Pur-alpha (Jin et al., 2007) and
thus prevent their normal function, or to the fact that the repeats
facilitate the generation or stabilization of a toxic protein that
results from translation of the FMR1 transcript that is initiated at
non-ATG codons (Todd et al., 2013).
THE CLINICAL PRESENTATION OF THE FXDs CAN BE VERY VARIABLE
A wide range of symptoms is seen in all three disorders and both
FXTAS and FXPOI are incompletely penetrant (Jacquemont et al.,
2004; Sullivan et al., 2005; Ennis et al., 2006; Allen et al., 2007;
Tejada et al., 2008; Hagerman, 2013). In the case of FM carriers,
a number of individuals do not meet the criteria for FXS having
only mild symptoms reminiscent of FXS and an IQ within or close
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to the normal range (Hagerman et al., 1994; Wohrle et al., 1998;
Taylor et al., 1999; Tassone et al., 2000b; Loesch et al., 2004, 2012;
Tabolacci et al., 2008a; Santa Maria et al., 2013).
Furthermore, it is becoming apparent that there is some over-
lap in the clinical symptoms in PM and FM carriers. For example,
small intranuclear inclusions characteristic of FXTAS have been
reported in males with FM alleles who still make some FMR1
mRNA and some FM carriers have symptoms and MRI ﬁndings
characteristic of FXTAS (Loesch et al., 2012; Santa Maria et al.,
2013). Conversely, symptoms of ADHD, seizures, shyness, social
deﬁcits, ASD and occasionally intellectual disability that are more
typical of FXS are also sometimes seen in PM carriers (Hager-
man et al., 1996; Farzin et al., 2006; Grigsby et al., 2006, 2007;
Hessl et al., 2007; Chonchaiya et al., 2012; Kim et al., 2014). In
addition, increased FMR1 transcription and/or FXTAS symptoms
have also been in reported in some carriers of FMR1 alleles that
have 45–54 repeats, so-called gray zone alleles (Kenneson et al.,
2001; Hall et al., 2011, 2012; Liu et al., 2013). These alleles have
also been suggested to contribute to the etiology of disorders asso-
ciated with parkinsonism (Loesch et al., 2007, 2009; Hall et al.,
2011; Trost et al., 2013). Some reports have also linked these alle-
les to ovarian dysfunction (Bretherick et al., 2005; Bodega et al.,
2006; Streuli et al., 2009; Ishizuka et al., 2011; Karimov et al., 2011;
Pastore et al., 2012; Barasoain et al., 2013) although others have
found no such association (Bennett et al., 2010; Voorhuis et al.,
2013; Murray et al., 2014).
REPEAT INSTABILITY AT THE FX LOCUS
The PM repeat tract is at risk of expansion on intergenera-
tional transmission in humans. There is also some evidence of
expansions occurring in some somatic tissues including the brain
(Lokanga et al., 2013). Both small and large expansions are seen.
Small expansions, which are seen more frequently on paternal
transmission, give rise to larger PM alleles that affect the risk of
FXTAS and FXPOI. The resultant larger alleles are also at increased
risk of further expansions (Heitz et al., 1992). Large expansions
give rise to FM alleles and these are exclusively maternally trans-
mitted (Rousseau et al., 1991; Nolin et al., 1996; Ashley-Koch et al.,
1998). In the gametes of male fetuses with FMs only FM alle-
les are observed (Malter et al., 1997), yet post-natally most FM
males only have PM-sized alleles in their sperm (Reyniers et al.,
1993; Rousseau et al., 1994). This would be consistent with the
idea that expansions can occur in both males and females but that
there is selection against large expansions during spermatogenesis.
While expansions predominate, contractions are also seen includ-
ing reversions of PM alleles into the normal size range (Mornet
et al., 1996; Vaisanen et al., 1996; Gasteiger et al., 2003; Tabolacci
et al., 2008b) and FMs into the PM range (Malzac et al., 1996;
Loesch et al., 1997). It is some combination of these expansions
and contractions that accounts for the repeat length mosaicism
that is often seen in PM and FM carriers (Rousseau et al., 1991;
Nolin et al., 1994; Prior et al., 1995; Cohen et al., 1996; de Graaff
et al., 1996; Dobkin et al., 1996; Maddalena et al., 1996; Mila et al.,
1996; Grasso et al., 1999; Petek et al., 1999; Schmucker and Seidel,
1999; Garcia Arocena et al., 2000; Fan et al., 2005; Govaerts et al.,
2007; Todorov et al., 2009; Ferreira et al., 2013; Pretto et al., 2013;
Santa Maria et al., 2013).
The mechanism of repeat instability is not fully understood.
Both strands of the FX repeats are able to form a variety of
intrastrand folded structures including hairpins and quadruplexes
containing a mixture of Watson–Crick and Hoogsteen base inter-
actions (Fry and Loeb, 1994; Mitas et al., 1995; Nadel et al., 1995;
Usdin and Woodford, 1995; Usdin, 1998; Fojtik and Vorlickova,
2001; Renciuk et al., 2009). The ability to form such structures is
a common feature of those diseases arising from repeat expan-
sion (reviewed in Usdin, 2008). This has led to the suggestion that
expansion arises from a problem related to the formation of these
structures. In addition to gender, two key factors have been iden-
tiﬁed that affect expansion risk in humans. These are the length of
the repeat tract and the presence or absence of AGG-interruptions
within the tract (Eichler et al., 1994; Zhong et al., 1996; Kunst
et al., 1997; Nolin et al., 2003, 2011, 2013; Yrigollen et al., 2012). In
vitro studies show that the presence of an AGG-repeat interrup-
tion diminishes the stability of the secondary structures formed
by a CGG-repeat tract (Weisman-Shomer et al., 2000; Jarem et al.,
2010). Thus the fact that AGG-interruptions reduce instability
would be consistent with a role of these structures in repeat
expansion.
Repeat instability has been studied in a number of mouse mod-
els of the PM (Bontekoe et al., 1997; Lavedan et al., 1998; Peier and
Nelson, 2002; Fleming et al., 2003; Entezam et al., 2007; Brouwer
et al., 2008). While small expansions are seen at a high frequency
in mouse models with ∼130 repeats, the large expansions char-
acteristic of the generation of a FM allele in humans are only
rarely seen in these animals. However, longitudinal studies of the
size of the transmitted allele in mice also demonstrates that alleles
can undergo multiple rounds of expansion over time, with the
changes in the repeat number in the transmitted allele increasing
with increasing repeat number (Lokanga et al., 2013; Zhao and
Usdin, 2014). This raises the possibility that the large expansions
seen in humansmay arise from the accumulated effect of a series of
small expansions. Since the perigametic interval, the time between
the last premeiotic cell division in the gamete of the parent and the
ﬁrst mitotic division in the offspring, usually lasts two decades or
more in humans compared to a few weeks or months in rodents,
humans have a much larger window of opportunity during which
repeat units can be added. The incremental accumulation of addi-
tional repeats with timemay also account for the observed parental
age effect on the risk of expansion seen in humans (Ashley-Koch
et al., 1998). In addition, PM alleles with 190 repeats show much
larger expansions than PM alleles that only have 130 repeats, rais-
ing the possibility that the threshold for large expansions is higher
in mice than it is in humans (Entezam et al., 2007).
MODELS FOR REPEAT EXPANSION
There are a number of different models for repeat expansion,
some of which are based on the idea that expansion results from
some problem associated with DNA synthesis through the repeats
during normal genomic replication and others that suggest that
expansion occurs as a result of aberrant repair of the secondary
structures formed by the repeats perhaps during transcription or
as a result of DNA damage (see Pearson et al., 2005; Mirkin, 2007
for comprehensive reviews). One of these models, the ORI-switch
model, proposes that expansion occurs during normal genome
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replication as the result of a switch or change in the origin of repli-
cation (ORI) used to replicate the locus in question. This switch
results in a change in thedirectionof replication through the repeat
(Mirkin and Smirnova, 2002). This switch could potentially occur
in the embryo when cell division is very rapid and additional ORIs
are needed to complete replication timeously. This model is pred-
icated on the premise that expansions and contractions occur via
strand-slippage during replication, a process more likely to occur
during lagging strand DNA synthesis. The most stable secondary
structure is thought to be the one most likely to promote slippage
since it would favor repriming of DNA synthesis from the slipped
position. Since the secondary structures formed by the CGG-
repeats are more stable than those formed by the CCG-repeats,
this model would predict that replication from an upstream ORI,
that results in the CGG-repeats being on the lagging strand tem-
plate, would favor contractions since repriming by the nascent
strand after strand-slippage would likely occur 5′ of the structure
on the template as illustrated in Figure 1A. In contrast, replication
from a downstream ORI would result in the CGG-repeats being
on the nascent Okazaki fragment and would thus favor expansions
since repriming by the nascent strand further 3′ on the template
would occur more often.
In normal human embryonic stem cells (ESCs) and in differen-
tiated cells with either normal or FX alleles, replication proceeds
equally well from ORIs located >45 kb upstream and downstream
of the repeat (Gerhardt et al., 2014). However, in FX ESCs replica-
tion proceeds predominantly from the downstream ORI such that
the CGG-strand would be on the Okazaki fragment consistent
with the requirements of the ORI-switch model (Gerhardt et al.,
2014). Since in somatic cells replication through the FMR1 locus
proceeds from both origins, the prediction of the model would be
that both expansions and contractions can occur with equal prob-
ability resulting in no net gain of repeats. In contrast, since in FX
ESCs replication proceeds predominantly from the downstream
ORI, expansions would predominate in these cells. However, since
the change in ORI usage seen in FX ESCs does not occur in nor-
mal ESCs, the switch in ORI site usage is not an intrinsic feature of
the FMR1 locus in this cell type. This raises the question of what
causes the ORI-switch in FX cells in the ﬁrst place. Further work
is needed to understand whether the change in ORI usage in FX
ESCs is a consequence of the expansion event that gave rise to the
FX allele or the cause. Since the FMR1 gene is already methylated
in the FX ESCs studied, it would be useful to examine ESCs from
individuals with unmethylated FMalleles to assess the role of DNA
methylation in ORI switching.
While it is possible that problems at the replication fork are
responsible for expansion, there are a number of lines of evidence
that support other types of models. For example, expansion is
known to be high in tissues with a low proliferative capacity like
brain and liver and in a mouse model of the FX PM expansion is
seen in post-mitotic cells such as oocytes and neurons (Lokanga
et al., 2013). This, along with data emerging from other repeat
expansion diseases, suggests that genomic replication may not be
required for expansion (Lia et al., 1998; Fortune et al., 2000; Ishig-
uro et al., 2001; Kovtun and McMurray, 2001; Lokanga et al., 2013,
2014b). Furthermore, oxidative damage has been shown to be risk
factor for expansion in a PM mouse model (Entezam et al., 2010),
supporting the idea that an aberrant DNA damage response rather
than a problem with replication may be responsible for expansion.
This idea is bolstered by the ﬁnding that mutations in the genes for
OGG1 and NEIL1, two DNA glycosylases involved in base excision
repair (BER) of oxidized bases, decrease the expansion frequency
in a mouse model of Huntington Disease, a Repeat Expansion Dis-
order involving CAG-repeats (Kovtun et al., 2007; Mollersen et al.,
2012).
The mismatch repair (MMR) protein MSH2 has been shown
to be essential for both intergenerational and germ line expan-
sions in the FX PM mouse (Lokanga et al., 2014b). MSH2 has also
been implicated in expansion in mouse models of other Repeat
Expansion Diseases (Manley et al., 1999; Savouret et al., 2003). In
addition to providing clues as to the mechanism of expansion,
the effect of parental Msh2-heterogosity in the FX PM mouse
also tells us something about the timing of these expansions.
Speciﬁcally, the Msh2−/− offspring of Msh2+/− parents have
the same expansion frequency as their Msh2+/+ and Msh2+/−
littermates. Thus, expansion events detected at birth are predomi-
nantly the result of expansion events occurring prezygotically. This
may be pertinent to the question of whether expansions seen on
intergenerational transmission in humans occur prezygotically or
postzygotically (Moutou et al., 1997; Reyniers et al., 1999; Huang
et al., 2014).
MSH2 likely binds the FX DNA hairpins as part of the MutSβ
complex, as reported for the hairpins formed by CAG/CTG-
repeats (Owen et al., 2005; Lang et al., 2011). MutSβ, a heterodimer
of MSH2 and MSH3, normally binds and triggers the repair of
insertion-deletion (IDL) loops of 1–15nucleotides. TheFX repeats
form hairpins with G•G and C•C mismatches (Mitas et al., 1995;
Usdin and Woodford, 1995; Yu et al., 1997; Usdin, 1998) and it
is likely that binding to the FX repeats occurs via the recognition
of these mismatched bases. However, whether MSH2 is acting
via classical MMR to recruit other MMR proteins or via another
DNA repair pathway, like BER, in which MSH2 also participates,
is currently unclear.
While expansion in the mouse model does not seem to require
genomic replication, it does require transcriptionally competent
chromatin since expansion only occurs when the PM allele is
situated on the active X chromosome (Lokanga et al., 2014a)
This is consistent with observations from humans, that methy-
lated alleles that are transcriptionally inactive, are stable (Wohrle
et al., 2001). Loss of Cockayne syndrome B (CSB), a protein
essential for transcription coupled repair (TCR), a DNA repair
pathway that is unique to actively transcribed genes, affects
germ line, and somatic expansion risk in the PM mouse (Zhao
and Usdin, 2014). It also causes a decrease in the extent of
somatic expansion in some organs but not others indicating
that CSB facilitates, but is not essential for expansion. Since
TCR requires CSB, its non-essential role suggests that the expan-
sion process does not involve TCR itself. It may be that CSB
is acting via its ability to facilitate steps in the BER path-
way (Muftuoglu et al., 2009; Menoni et al., 2012; Aamann et al.,
2013).
Since TCR is not essential for somatic expansions, the fact
that expansion only occurs on the active X chromosome must
have a different molecular basis. It may simply be that occlusion
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FIGURE 1 | Models for intergenerational repeat instability at the FX
locus. In both models the CGG-rich strand, which forms the most stable
secondary structure, is shown in red and the CCG-rich strand is shown in
green. (A) ORI-switch model for FX repeat instability. The FMR1 gene is
ﬂanked by two ORIs, one located 45 kb upstream (5′) and another 45 kb
downstream (3′) of the gene (Gerhardt et al., 2014). During replication
transient dissociation of the Watson and Crick strands of DNA can occur
with slippage of the two strands relative to one another. Priming of DNA
synthesis can then occur from the slipped position. This strand-slippage
process is thought to occur more commonly during lagging strand
replication and is seen more frequently when the template or nascent
strand have the potential to form secondary structures. Secondary structure
formation by the lagging strand template would result in loss of
repeats/contractions since repriming 5′ of the structure on the template
would be favored, while the formation of such structures on the
corresponding Okazaki fragment would favor addition of repeats since
repriming would then be more likely to occur more 3′ on the template.
Replication from the upstream ORI results in the CGG-rich strand being on
the lagging strand template (note that only one side of the bidirectional
replication fork is shown). In contrast, replication from the downstream ORI
results in the CGG-rich strand being on the Okazaki fragment. In somatic
cells replication proceeds equally well from both ORIs resulting in no net
gain of repeats. However, in FX ESCs it is suggested that replication
predominantly occurs from the downstream ORI resulting in a net gain of
repeats. (B) A DNA repair based model for FX repeat instability. During
transcription, RNA Polymerase II (Pol II) occludes the template strand,
leaving the non-template strand free to form secondary structures.
Secondary structure formation may also be facilitated by the
co-transcriptional formation of stable RNA:DNA hybrid in the repeat region
(Loomis et al., 2014). These structures are then processed via an
MSH2-dependent expansion pathway in which CSB plays a supportive role.
This pathway is initiated by binding of the MSH2-containing complex to the
mismatches in the structures. Events downstream of this binding are not
currently known. One possibility is that classical mismatch repair is initiated
in response to MSH2 binding but that hairpins form in the ﬂaps generated
by strand displacement synthesis as part of this repair. Hairpin formation
may prevent normal removal of these bases by ﬂap endonucleases (Spiro
et al., 1999) resulting in their incorporation into the “repaired” strand.
of the template strand by the RNA polymerase II (Pol II) dur-
ing transcription increases the opportunity for the formation of
the secondary structures on the non-template strand that act as
the substrates for expansion. Alternatively, the effect of transcrip-
tion may be mediated via the formation of persistent RNA:DNA
hybrids or R-loops at the FMR1 locus (Loomis et al., 2014). These
R-loops may allow the expansion substrates to form because rean-
nealing of the duplex behind Pol II cannot take place. These
data suggest a model for repeat instability in which transcription
results in the formation of the secondary structures that act as
the substrate for the MSH2-dependent, CSB-facilitated expansion
pathway as illustrated in Figure 1B.
POTENTIAL APPROACHES TO REDUCING EXPANSION RISK
While repeat length and purity seem to be the most important
factors driving expansion of PM alleles in humans, it may be that
other genetic or environmental factors contribute to expansion
risk in smaller PM alleles or in gray zone/intermediate alleles.
The fact that ATM protects the genome against repeat expansion
in mice (Entezam and Usdin, 2008, 2009) is of interest in this
regard since ATM mutations are relatively common in the human
population (Swift et al., 1986) and may thus be a relatively com-
mon source of variability in the extent of expansion in carriers of
smaller alleles. Our demonstration that oxidative stress increases
expansion risk in mice is of general interest since there are many
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sources of oxidative stress to which both rodents and humans are
exposed. These include internal sources, resulting from normal
metabolism, and external sources in the form of environmen-
tal pollutants, ionizing and ultraviolet radiation, heat shock, and
sources of inﬂammation. However, whether dietary antioxidants
can protect against expansions is not known.
The contribution of the MSH2 binding partners MSH3 and
MSH6 to repeat expansion in FX or the FX PM mice is not known.
However, while MSH6 has been shown to be important for expan-
sion in Friedreich ataxia (FRDA) induced pluripotent stem cells
(Du et al., 2012), in mouse models of other repeat expansion dis-
eases, it is MSH3 that is important (van den Broek et al., 2002;
Foiry et al., 2006; Tome et al., 2013). It has been suggested that the
development of MSH3 inhibitors may have therapeutic potential
since loss of MSH3 is less deleterious than the loss of either MSH2
or MSH6 (Foiry et al., 2006; Halabi et al., 2012). Furthermore,
the data suggest that improving the efﬁcacy of the pathways that
lead to contractions or error-free repair could in principle reduce
expansion risk.
REPEAT-MEDIATED EPIGENETIC EFFECTS
Curiously, CGG-repeats can both enhance and repress FMR1 gene
expression, causing hyperexpression of PM alleles and hypoex-
pression or silencing of FM alleles. The mechanisms involved are
not at all well understood.
HYPEREXPRESSION OF THE PM ALLELE
Fragile X mental retardation 1 mRNA is expressed at elevated lev-
els in cells of humans (Tassone et al., 2000c) and mice with the
PM allele (Entezam et al., 2007; Brouwer et al., 2008). These lev-
els are directly related to repeat number and can be as high as
10 times that of the FMR1 transcript in normal cells. Since the
pathology seen in PM carriers is thought to be related either to
the ability of the RNA to sequester proteins or the toxic pro-
teins that can be made from the PM transcripts, the elevated
levels of PM mRNA is likely to contribute to disease severity.
The increased RNA levels are the result of increased transcrip-
tion initiation rather than increased transcript stability (Tassone
et al., 2007). Thus the CGG-repeats may act as a downstream
enhancer/modulator of transcription. The increase in mRNA is
also correlated with changes in transcription start site usage in
which larger PM alleles initiate transcription from upstream start
sites more frequently than occurs in normal cells (Beilina et al.,
2004). This is suggestive of an altered chromatin conformation on
the PM allele.
The increase in FMR1 transcription in PM carriers is known to
be associated with an increased abundance of acetylated histones
at the FMR1 promoter (Todd et al., 2010), however, whether this
is a cause or consequence of the increased transcription remains
to be determined. Long tracts of CGG-repeats have been shown
to exclude nucleosomes in vitro (Wang et al., 1996). Should this
also occur in vivo it could potentially lead to increased tran-
scription by increasing the accessibility of transcription factors
to the promoter. The R-loops formed by the CGG-Repeats (Groh
et al., 2014; Loomis et al., 2014) could also play a role in FMR1
hyperexpression. R-loops may be less prone to assemble nucleo-
somes (Dunn and Grifﬁth, 1980) and more prone to chromatin
decondensation (Powell et al., 2013). The effect of the longer R-
loops formed on an expanded repeat may extend further into the
ﬂanking regions perhaps enhancing binding of the promoter by
transcription factors or chromatin modiﬁers that in turn pro-
mote transcription initiation. It is also possible that the FX repeats
directly bind factors that can remodel chromatin or regulate FMR1
transcription. For example, pur alpha and pur beta are multifunc-
tional proteins that can bind CGG-repeats very effectively and in
some contexts are known to activate transcription (Huang et al.,
2009).
REPEAT-MEDIATED GENE SILENCING OF FM ALLELES
Most FM alleles are largely or completely silenced. How this
silencing is accomplished is not well understood or how it is
that some carriers of FM alleles escape this silencing. The 5′ end
of the FMR1 gene in FXS-derived patient cell lines is hyperme-
thylated and associated with hypoacetylated histones (Chiurazzi
et al., 1998, 1999; Coffee et al., 1999; Pietrobono et al., 2002, 2005;
Biacsi et al., 2008). In addition, histone H3 is hypomethylated on
lysine 4 (H3K4) on FX alleles and enriched for dimethylated H3K9
and trimethylated H3K27, marks typical of developmentally reg-
ulated genes, as well as trimethylated H3K9 and trimethylated
H4K20, marks typically seen on constitutive heterochromatin
like the tandem repeats that make up the pericentric hete-
rochromatin (Kumari and Usdin, 2010). However, when these
modiﬁcations are deposited and the sequence of events involved
is unclear.
A study of FMRP expression in chorionic villi (CV) of two male
Fragile X fetuses led to the suggestion that silencing of the FX allele
occurs in the CV between 10 and 12.5 weeks of age (Willemsen
et al., 2002). However, in other studies DNA methylation of the
FX allele was already detectable in CV samples of 8–10 week old
fetuses (Devys et al., 1992). In general, reprogramming of DNA
methylation is thought to occur earlier in the embryo than in
trophectoderm-derived cell lineages (Santos et al., 2002). Whether
FX gene methylation also occurs earlier in the embryo remains to
be seen but would be consistent with the observation that 2 out of
the 3 ESC lines that have been derived so far are alreadymethylated
(Colak et al., 2014; Gerhardt et al., 2014).
In a study of an unmethylated FX ESC line, teratomas derived
from these ESCs showed a ∼20-fold reduction in transcription
along with enrichment for H3K9 methylation, while the DNA was
still unmethylated (Eiges et al., 2007). This suggests DNA methyla-
tion is a relatively late event in the silencingprocess. Other evidence
that supports this idea is the fact that carriers of unmethylated
FM alleles (UFMs) show evidence of H3K9 dimethylation char-
acteristic of silenced alleles but no DNA or H3K27 methylation
(Tabolacci et al., 2008a). Furthermore, treatment of patient cells
with the demethylating agent 5-azadeoxycytidine (AZA) reduces
DNA methylation but does not affect the levels of H3K9 methy-
lation (Chiurazzi et al., 1998, 1999; Coffee et al., 1999; Pietrobono
et al., 2002, 2005; Biacsi et al., 2008). The idea that DNA methy-
lation is a relatively late event in the silencing process would be
consistent with the observation that de novo methylation of many
other genes is associated with prior histone methylation (Feldman
et al., 2006; Vire et al., 2006; Dong et al., 2008; Epsztejn-Litman
et al., 2008; Tachibana et al., 2008).
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A contrasting picture of events emerges from a study of two
other ESC lines. In these cells H3K9 dimethylation and loss of
FMR1 transcription was only seen after >45 days of neuronal
differentiation (Colak et al., 2014). However, the FM allele in these
ESCs was already at least partially methylated as evidenced by the
resistance of the promoter to Eag I digestion. Thus presumably
early events in the silencing process had already taken place prior
to neuronal differentiation. Nonetheless, these data suggest that
in this system H3K9 dimethylation occurs many weeks after DNA
methylation had begun, an observation that is perplexing given
the normally close linkage between these events.
A key unresolved question in the ﬁeld is what is the trigger for
gene silencing. The distribution of histone modiﬁcations on the
FX allele may provide some insight into where the target may be.
For example, H3K9me3 and H4K20me3, marks typical of consti-
tutive heterochromatin, show a peak of enrichment in the region
of the repeat, while the other histone modiﬁcations are more uni-
formly distributed across the 5′ end of the gene. The enrichment of
H3K9me3 and H4K20me3 would be consistent with the idea that
the repeats themselves are the early target of the silencing process.
Deposition of other histone marks more typical of developmen-
tally regulated genes onto the FMR1 5′ end may be a consequence
of the loss of a proposed boundary element located between the
FMR1 gene and the zone of heterochromatin found upstream of
the FMR1 gene on normal and affected alleles (Kumari and Usdin,
2010). The nature of the boundary element is unclear but while
CCCTC-binding factor (CTCF) binds to this region, this factor is
unlikely to be involved (Lanni et al., 2013). It is also possible that
the broader distribution of H3K9me2 and H3K27me3 reﬂects a
greater ability of these heterochromatin marks to spread than the
marks of constitutive heterochromatin. In either event, the data
support the idea that the initiation of silencing begins in the repeat
itself (Kumari and Usdin, 2010).
Models for the initiation of gene silencing fall into two basic
groups, one in which the DNA itself recruits factors that ultimately
result in the accumulation of repressive chromatin and the other
in which RNA produced locally or distally in the form of short or
long coding or non-coding RNAs is the trigger.
DNA-based models for the nucleation of silencing
The secondary structures formed by the repeats are known to be
particularly good substrates for DNA methyltransferases in vitro
(Smith et al., 1994). This has led to a model in which hairpin for-
mation by the repeats in DNA triggers de novo DNA methylation
as the ﬁrst step in the silencing process as illustrated in the left
hand panel of Figure 2A. However, if DNA methylation were in
fact a later event in the silencing process, then this model would
presumably not apply.
An alternatemodel forDNA-based initiation of silencing is seen
in pericentromeric repeats in mice that occurs when the transcrip-
tion factors Pax3 andPax9 bind to the repeats and recruit theH3K9
trimethylase, Suv39h1 (Bulut-Karslioglu et al., 2012) as illustrated
in the right hand panel of Figure 2A. The repeats that bind Pax3
and Pax9 are A+T-rich making it unlikely that the same factors
bind to the FX repeats. However, it has been suggested that other
repeat-binding proteins may act in the same way to bring about
gene silencing (Bulut-Karslioglu et al., 2012).
RNA-based models for the nucleation of silencing
The FMR1 locus produces a complex mixture of sense and anti-
sense transcripts that could potentially trigger gene silencing in
a variety of other ways (Ladd et al., 2007; Kumari and Usdin,
2010; Pastori et al., 2014). The CGG-repeats in RNA can form
hairpins that are substrates for the enzyme Dicer, an important
component of the RNA interference (RNAi) pathway (Handa
et al., 2003). In mammals this pathway is usually associated with
the post-transcriptional regulation of mRNAs but in ﬁssion yeast
it can also lead to transcriptional gene silencing of centromeric
repeats (Volpe et al., 2002). Dicer processes RNAs with double-
stranded character into small interfering RNAs that, at least in
yeast, are loaded onto the RNA-induced transcriptional silenc-
ing (RITS) complex. This complex can lead to gene silencing via
the recruitment of Swi6/HP1 and a protein with similarities to
the mammalian Suv39h protein (Nakayama et al., 2001; Rouge-
maille et al., 2012). Whether such a system operates in mammals
is the subject of some debate. Work in human cells suggests that
an analogous process does operate as illustrated in the right hand
panel of Figure 2B (Kim et al., 2006). However, no evidence of
abnormal methylation is seen at other CGG-repeat tracts in the
human genome (Alisch et al., 2013). It is possible that the repeat
number at any given locus has to exceed a certain threshold in
order to be susceptible to silencing (Alisch et al., 2013). Such a
threshold effect might also explain why the FM alleles are not
silenced in mouse models for expanded repeats (Entezam et al.,
2007; Brouwer et al., 2008). It is also possible that the silencing
mechanism acts only in cis. Work done in neurons differentiated
from FX ESCs suggested that Dicer is not required for either shut-
ting down transcription of the FMR1 gene or for dimethylation of
H3K9 (Colak et al., 2014). However, since these cells were already
at least partially methylated before differentiation began, a role
for Dicer in the earliest steps of the silencing process cannot be
excluded.
A number of Dicer-independent RNA-mediated silencing
mechanisms are also possible. One such mechanism is related
to the reported ability of the CGG-repeats to form persistent
RNA:DNA hybrids (R-loops; Colak et al., 2014; Groh et al., 2014;
Loomis et al., 2014). An R-loop containing the repeat is seen at
the FMR1 locus in neurons derived from FX ESCs. This R-loop
appears after 45 days of differentiation and is followed by silenc-
ing of the FMR1 gene (Colak et al., 2014). In these experiments
no R-loop was seen in normal ESCs or cells from patients with
FXTAS. A small molecule that is thought to block R-loop forma-
tion prevents gene silencing supporting the idea that the R-loop
is crucial for this process. However, since some DNA methyla-
tion is already apparent in the ESCs prior to differentiation, it
is likely that other events in the silencing process precede the
action of the RNA:DNA hybrid. Why the R-loop is only seen in
this small window of time is unclear, particularly since they can
be readily detected in differentiated dermal ﬁbroblasts even on
shorter alleles (Loomis et al., 2014). Furthermore, why so much
time elapses between the initiation of DNA methylation and the
other epigenetic modiﬁcations that lead to silencing is also per-
plexing. However, there are a number of ways that R-loops could
trigger silencing of the FX allele. They may cause transcription
termination directly as do the R-loops generated by the repeat
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FIGURE 2 | Models for FX gene silencing. Potential early steps in the
initiation of FX gene silencing are depicted. (A) Two ways in which silencing
can be triggered by the FX DNA. The left hand panel depicts a model based
on the propensity of DNA methyltransferases to methylate FX hairpins in
vitro (Smith et al., 1994; Chen et al., 1995). The right hand panel depicts a
silencing scheme in which repeat binding proteins act to recruit silencing
complexes based on the silencing mechanism that is thought to be
responsible for the silencing of the major satellite repeats in pericentric
heterochromatin in mice (Bulut-Karslioglu et al., 2012). In the case of the
major satellite repeats recruitment of Suv39h leads to the recruitment of
DNA methylases and SUV4-20H which trimethylates H4K20. DNMT: DNA
methyltransferase; TF: transcription factor; TSS: transcription start site.
(B) Two ways in which RNA-mediated gene silencing might occur in the FX
locus. The left hand panel depicts an RNA interference based mechanism
for gene silencing based on the model of silencing of centromeric tandem
repeats in the ﬁssion yeast, Schizosaccharomyces pombe (Volpe et al.,
2002). In the FX locus the RNA hairpins formed by the FX repeats in the
FMR1 transcript may be the source of the double-stranded Dicer (Dcr)
substrates (Handa et al., 2003) as illustrated. In this case the annealing of
the small Dicer products to the FMR1 mRNA would occur via the same
combination of Hoogsteen and Watson–Crick base pairing that generates
the RNA hairpins in the ﬁrst place. Alternatively, the duplex RNAs could be
generated by base pairing of FMR1 mRNA with an antisense transcript
generated from this region (Ladd et al., 2007). The RNA-induced
transcriptional silencing (RITS) complex, which includes the argonaute
family member AGO1, then could mediate heterochromatin formation by
associating with nascent transcripts via base pairing with the Dcr products.
AGO1 could then recruit other epigenetic modiﬁers including members of
the Polycomb (PcG) Group Complexes including EZH2 as suggested by
work in human cells (Kim et al., 2006). The right hand panel depicts a way
in which an RNA:DNA hybrid may initiate silencing by tethering the FMR1
transcript to the FMR1 locus while also recruiting silencing complexes (SC)
that bind to the repeat, perhaps to the secondary structures formed by the
repeat, analogous to what has been reported for the RASSF1A locus
(Beckedorff et al., 2013) and for ribosomal DNA repeats and IAP elements
(Bierhoff et al., 2014). Dcr1: Dicer 1; Pol II: RNA Polymerase II; RITS: RNA
interference (RNAi) effector complex; SC: silencing complex; TSS:
transcription start site.
that causes the Repeat Expansion Diseases, amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration (FLTD;
Haeusler et al., 2014) or recruit a transcriptional repressor as sug-
gested for the COOLAIR locus in Arabidopsis (Sun et al., 2013).
Reduced transcription could then result in the accumulation of
repressive histone marks. It is also possible that silencing occurs
due to the ability of RNA:DNA hybrids to recruit H3S10P, a mark
of chromatin compaction (Castellano-Pozo et al., 2013).
An alternative model for FX gene silencing is suggested by
what is known about silencing of the RASSF1A gene in humans.
This is accomplished by the formation of RNA:DNA hybrid just
downstream of the start of transcription by transcription from an
antisense promoter (Beckedorff et al., 2013). The tethered RNA
binds and recruits Polycomb repressive complex 2 (PRC2) to the
RASSF1A promoter resulting in gene silencing. An example of
how an RNA:DNA hybrid could operate to recruit factors that ini-
tiate silencing at the FMR1 locus is illustrated in the right hand
panel of Figure 2B. The FMR1 5′ end has some of the hallmarks
of typical PRC2 target genes, including a high G+C-content and
a high density of CpG residues (Mendenhall et al., 2010). Fur-
thermore, there is evidence to suggest that many RNAs that bind
to PRC2 and lead to gene silencing in cis form stem-loop struc-
tures (Kanhere et al., 2010) that are reminiscent of those formed
by CGG-RNA (Handa et al., 2003). Other candidate epigenetic
modiﬁers that bind structured RNAs could act in much the same
way, including Suv4-20h2, the methylase responsible for H4K20
trimethylation. Recruitment of this histone methyltransferase by
a long non-coding RNA (lncRNA) is thought to be the trigger
for silencing of rDNA repeats and intracisternal A-particle (IAP)
elements (Bierhoff et al., 2014).
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Whatever the gene silencing mechanism, evidence suggests
that the extent of this process can be very variable. Some FM
carriers do not complete the gene silencing process, showing
evidence of H3K9 dimethylation, but no DNA methylation (Tabo-
lacci et al., 2008a). These individuals tend to be unaffected or less
affected than those having alleles that are fully silenced. Other
individuals show methylation mosaicism in which some alleles
are more heavily methylated than others (McConkie-Rosell et al.,
1993; Nolin et al., 1994; Rousseau et al., 1994; de Vries et al., 1996;
Tassone et al., 1999; Pretto et al., 2014). Since unmethylated alle-
les often still make signiﬁcant amounts of FMRP (Tassone et al.,
2000a; Tabolacci et al., 2008a), methylation mosaicism likely con-
tributes to variation in the levels of FMRP expressed in patient
cells that is potentially a source of variability in the clinical
presentation.
A number of epigenetic modifying drugs with the potential to
reactivate the FMR1 gene are in clinical trials for the treatment
of life-threatening diseases like cancer, as well as other repeat
expansion diseases with a high early mortality like FRDA and
spinalmuscular atrophy (Hahnen et al., 2006; Deutsch et al., 2008).
Phase I clinical trials of one such compound, the HDAC inhibitor
RG2833, showed that it could reduce epigenetic gene repression
in FRDA patients. It is likely that many of these epigenetic mod-
iﬁers will be too risky to use in a disorder like FXS that is not life
threatening. However, there are others in the pipeline that may
be both therapeutically useful and relatively non-toxic. One such
compound, nicotinamide (Vitamin B3), an inhibitor of SIRT1,
an enzyme we have shown to be important in FX gene silencing
(Biacsi et al., 2008), is currently in clinical trials for the treatment
of FRDA (http://www.clinicaltrials.gov/ct2/show/NCT01589809).
The development of better inhibitors of SIRT1 as well as other epi-
genetic modifying enzymes in the silencing pathway may one day
provide a therapeutic option for the treatment of FXS. Recently a
small molecule that stabilizes the structures formed by FX repeats
in the FMR1 transcript and thus reduces R-loop formation, has
been shown to block gene silencing (Colak et al., 2014). While this
moleculewas unable to reactivate a silenced allele, it is possible that
in combination with other epigenetic modiﬁers it may ultimately
have therapeutic potential. Of course, any beneﬁt to be gained
by reactivation of the FX allele would have to be offset by the
risk posed by expression of FMR1 mRNA with long CGG-repeat
tracts.
CHROMOSOME FRAGILITY
Fragile sites are constrictions, gaps or breaks that are seen in
metaphase chromosomes [see (Lukusa and Fryns, 2008) for a com-
prehensive review]. Many such sites are present in the human
genome where they are frequently associated with chromosome
breakpoints and translocations. Fragile sites are said to be com-
mon or rare based on their incidence in the population, with
common fragile sites being ubiquitously present and rare frag-
ile sites being conﬁned to a much smaller subset of individuals.
Fragile sites are usually classiﬁed in terms of which agents most
effectively induce their expression. These agents include folate,
aphidicolin, distamycin, and bromodeoxyuridine. The presence
of a folate-sensitive fragile site on the long arm of the X chromo-
some in individuals with FXS was noted many decades before the
FMR1 gene was identiﬁed (Howard-Peebles and Stoddard, 1979;
Sutherland and Ashforth, 1979; Turner et al., 1980). The fragile
site can be seen in as many as 20% of cells depending on repeat
number and growth conditions. This indicates that the underlying
event is likely to be extremely frequent.
There is reason to think that the high incidence of TS seen in FM
females (Dobkin et al., 2009) could be a direct consequence of the
chromosome fragility. For example, simultaneous breaks on both
chromatids can lead to chromatid fusion, and the generation of a
dicentric chromosome. The two centromeres of the chromosome
will try to migrate toward opposite poles at anaphase. Chromo-
some aneuploidy can then occur through non-disjunction, if the
dicentric chromatid is only released from one pole, resulting in
one daughter cell receiving the whole chromosome at the expense
of the other daughter cell. Alternatively, if the dicentric chromatid
frees itself from the microtubules of both spindle poles, it can be
lost from both cells as a result of anaphase lagging.
There are some clues as to what causes the FX allele to become
fragile and/or break. Folate is a critical precursor for the synthe-
sis of thymidine and too much or too little of this vitamin can
cause nucleotide pool imbalances (James et al., 1992) that might
cause or exacerbate problems with replication (Chabosseau et al.,
2011) through the repeat. The FX repeats cause replication fork
stalling in yeast and human cells (Voineagu et al., 2009). They
also block initiation of replication from a major ORI located
just upstream of the repeat in the FMR1 gene itself and likely
affect replication fork progression as well (Yudkin et al., 2014).
This block is seen even in cells grown in the absence of folate-
stress and thus the replication problem is likely an intrinsic
feature of the repeats that occurs frequently under normal growth
conditions. Folate-stress could induce fragile site expression by
making an already late-replicating region (Webb, 1992; Hansen
et al., 1993) replicate even later. This would increase the frac-
tion of cells that enter mitosis before replication of this region
is complete. What is responsible for the replication defect is
unknown. R-loops, such as those formed by the FX repeats (Groh
et al., 2014; Loomis et al., 2014), can stall DNA replication (Gan
et al., 2011). However, chromosome fragility is more frequently
seen on methylated FM alleles than unmethylated ones (Yudkin
et al., 2014). It is unclear whether the residual transcription from
methylated alleles is sufﬁcient to cause stalling at a signiﬁcant fre-
quency. It is also possible that the secondary structures that can
be formed by the FX repeat are responsible for the replication
problem since they do form very stable blocks to DNA poly-
merases in vitro (Usdin and Woodford, 1995). Whatever their
molecular basis, stalled replication forks can result in double-
strand breaks generated in an attempt to rescue the fork. Such
breaks could then lead to sister chromatid fusion and ultimately
the loss of the X chromosome from a fraction of the daughter
cells.
Thus each cell division poses a risk for the loss of the chro-
mosome carrying the FM. If chromosome loss happens in the
very early embryo, it is unlikely to survive (Hook and Warburton,
1983). However, if it occurs later in development, females will be
mosaic for the loss of the X chromosome. The extent to which
she would experience the symptoms of TS would depend on the
fraction of her cells that are 45, X0.
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CONCLUDING REMARKS
As evidenced above, the presence of CGG/CGG -repeats at the 5′
end of the FMR1 gene causes a number of genetic and epigenetic
changes that can have profound effects on the FMR1 locus and
FMR1 expression. These effects are, for the most part, expressed
in direct proportion to the number of repeats in the affected allele.
Thus unlike point mutations or insertions/deletions, the dynamic
nature of the expansion mutation essentially makes the FX repeat
a continuous variable, at least on the population level. Thus per-
haps it should not be surprising that the symptoms seen in carriers
of larger than normal numbers of CGG/CCG repeats form a con-
tinuum. Therefore, it may be more useful to think of as these
individuals being somewhere on the Fragile X spectrum, such that
the symptoms experienced may range from a risk of neurode-
generative changes or diminished ovarian function at one end of
the spectrum to severe neurodevelopmental problems at the other.
The range of symptoms displayed would depend on the number of
repeats in the affected allele and the extent of somatic mosaicism
that would impact the amount of FMR1 mRNA and FMRP pro-
duced in critical cell types. A better understanding of all of the
biological consequences of the repeats at both the DNA and RNA
level may help us understand which of the effects can be mitigated
and which ones cannot.
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